S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NASDAQ:MACKMerrimack Pharmaceuticals Stock Price, Forecast & News

$3.59
+0.27 (+8.13 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.40
Now: $3.59
$3.67
50-Day Range
$3.10
MA: $3.30
$3.51
52-Week Range
$1.49
Now: $3.59
$7.09
Volume103,191 shs
Average Volume35,649 shs
Market Capitalization$48.03 million
P/E RatioN/A
Dividend YieldN/A
Beta2.45
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Read More
Merrimack Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.30 per share

Profitability

Net Income$-17,330,000.00

Miscellaneous

Employees27
Market Cap$48.03 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable
$3.59
+0.27 (+8.13 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

How has Merrimack Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Merrimack Pharmaceuticals' stock was trading at $2.76 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MACK shares have increased by 30.1% and is now trading at $3.59.
View which stocks have been most impacted by Coronavirus
.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Merrimack Pharmaceuticals
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported $0.02 EPS for the quarter.
View Merrimack Pharmaceuticals' earnings history
.

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals declared a -- dividend on Wednesday, December 4th. Stockholders of record on Monday, December 16th will be paid a dividend of $0.50 per share on Monday, December 23rd. The ex-dividend date is Friday, December 13th.
View Merrimack Pharmaceuticals' dividend history
.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Merrimack Pharmaceuticals's stock reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Has Merrimack Pharmaceuticals been receiving favorable news coverage?

Media headlines about MACK stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Merrimack Pharmaceuticals
.

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a increase in short interest in July. As of July 15th, there was short interest totaling 530,400 shares, an increase of 8.4% from the June 30th total of 489,200 shares. Based on an average daily volume of 25,900 shares, the days-to-cover ratio is presently 20.5 days. Approximately 4.1% of the company's shares are sold short.
View Merrimack Pharmaceuticals' Current Options Chain
.

Who are some of Merrimack Pharmaceuticals' key competitors?

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC), Exelixis (EXEL) and Verastem (VSTM).

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the following people:
  • Dr. Richard Peters, Pres, CEO & Director (Age 56)
  • Ms. Jean M. Franchi, CFO & Treasurer (Age 53)
  • Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)
  • Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)
  • Dr. Sergio L. Santillana, Chief Medical Officer (Age 56)

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $3.59.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $48.03 million. Merrimack Pharmaceuticals employs 27 workers across the globe.

What is Merrimack Pharmaceuticals' official website?

The official website for Merrimack Pharmaceuticals is www.merrimackpharma.com.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.